Welcome to our dedicated page for Barinthus Biotherapeutics plc SEC filings (Ticker: BRNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Barinthus Biotherapeutics plc (BRNS) SEC filings page on Stock Titan provides access to the company’s official U.S. regulatory disclosures as filed with the Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biopharmaceutical company focused on immunology and inflammation, Barinthus Bio uses SEC filings to report on its financial condition, clinical development progress, strategic transactions, and governance matters.
Investors researching BRNS can review current reports on Form 8-K, which Barinthus Bio uses to announce material events such as quarterly and annual financial results, strategic business updates, and key clinical milestones. Recent 8-K filings have furnished press releases detailing the company’s strategic focus on immunology and inflammation, progress in the Phase 1 AVALON trial of VTP-1000 for celiac disease, data from Phase 2 trials of VTP-300 in chronic hepatitis B, and restructuring measures intended to extend the company’s cash runway.
The filings page also includes transaction-related disclosures. Barinthus Biotherapeutics plc has filed an 8-K describing its entry into a definitive merger agreement with Clywedog Therapeutics, Inc. and outlining the structure of the proposed combination. These documents explain how a new holding company would acquire Barinthus Biotherapeutics plc and Clywedog, the expected ownership split between existing shareholders, the planned new name Clywedog Therapeutics, Inc., and the expectation that the combined company will trade on Nasdaq under the ticker symbol CLYD upon closing, subject to approvals and conditions.
Through Stock Titan, users can follow real-time updates from EDGAR as new BRNS filings are posted, including amendments such as Form 8-K/A used to correct or clarify previously furnished information. The platform’s AI-powered tools can help summarize lengthy filings, highlight key sections on clinical programs like VTP-1000 and VTP-300, and surface important terms in merger agreements and restructuring announcements. In addition, users can review equity-related disclosures, including information referenced in filings about equity awards and the treatment of options and restricted share units in connection with the proposed combination.
This filings archive is a resource for understanding how Barinthus Bio reports its financial performance, communicates clinical and corporate developments, and documents the regulatory steps involved in its planned combination with Clywedog Therapeutics.
Q2-25 snapshot: Barinthus Biotherapeutics (BRNS) posted a net loss of $21.1 million (-24.6 % YoY) or -$0.52/sh; six-month loss widened to $40.8 million. Cash & equivalents fell to $86.3 million from $110.7 million at FY-24, but management still forecasts liquidity into early-2027.
Expense trends: R&D dropped 32 % YoY to $8.0 million as infectious-disease and oncology projects were shelved; however, G&A more than doubled to $15.4 million due mainly to an $8.0 million foreign-exchange loss and restructuring costs, lifting total operating spend 24 % to $23.3 million.
Balance sheet & risk: Current assets declined 20 % to $100.4 million; equity slid to $102.5 million. There is no debt, but cash burn averaged ~$17 million per quarter, and accumulated deficit reached $278.4 million.
Pipeline focus: Strategy now centres on immunology & inflammation. Lead SNAP-TI asset VTP-1000 (celiac disease) has completed dosing of two single-ascending-dose cohorts; topline safety/biomarker data expected early Q4-25. VTP-300 (HBV) will finish current Phase 2 trials while partnering options are explored; CEPI-funded MERS vaccine program is being exited.
Key watch-points: 1) VTP-1000 Phase 1 read-out, 2) ability to rein in G&A, 3) partnership progress for VTP-300, and 4) sustaining cash runway under current burn.